When to start aripiprazole therapy in patients with bipolar mania

References

• YoungAHRigneyUShawSEmmasCThompsonJMAnnual cost of managing bipolar disorder to the UK healthcare systemJ Affect Disord201113345045621737141
   PubMed Web of Science ®Google Scholar
• American Psychiatric AssociationDiagnostic and Statistical Manual of Mental Health Disorders: DSM-55th edWashington, DCAmerican Psychiatric Publishing2013
   Google Scholar
• PacchiarottiIBondDJBaldessariniRJThe International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disordersAm J Psychiatry2013170111249126224030475
   PubMed Web of Science ®Google Scholar
• GrunzeHVietaEGoodwinGMThe World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute maniaWorld J Biol Psychiatry2009108511619347775
   PubMed Web of Science ®Google Scholar
• GrunzeHVietaEGoodwinGMWFSBP Task Force on Treatment Guidelines for Bipolar Disorders. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorderWorld J Biol Psychiatry20131415421923480132
   PubMed Web of Science ®Google Scholar
• GrunzeHVietaEGoodwinGMWFSBP Task Force On Treatment Guidelines For Bipolar Disorders. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2010 on the treatment of acute bipolar depressionWorld J Biol Psychiatry2010118110920148751
   PubMed Web of Science ®Google Scholar
• ParkMHHanCPaeCUAripiprazole treatment for patients with schizophrenia: from acute treatment to maintenance treatmentExpert Rev Neurother2011111541155222014131
   PubMed Web of Science ®Google Scholar
• BurrisKDMolskiTFXuCAripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptorsJ Pharmacol Exp Ther200230238138912065741
   PubMed Web of Science ®Google Scholar
• JordanSKoprivicaVChenRThe antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT(1A) receptorEur J Pharmacol200244113714012063084
   PubMed Web of Science ®Google Scholar
• ShapiroDARenockSArringtonEAripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacologyNeuropsychopharmacol20032814001411
   PubMed Web of Science ®Google Scholar
• KeckPEJrMcElroySLAripiprazole: a partial dopamine D2 receptor agonist antipsychoticExpert Opin Investig Drugs2003124655662
   PubMed Web of Science ®Google Scholar
• Abilify® (aripiprazole) [US prescribing information] (online)New YorkBristol-Myers Squibb Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021436s037,021713s029,021729s021,021866s022lbl.pdfAccessed September 27, 2013
   Google Scholar
• TadoriYForbesRAMcQuadeRDKikuchiTCharacterization of aripiprazole partial agonist activity at human dopamine D3 receptorsEur J Pharmacol20085971–3273318831971
   PubMed Web of Science ®Google Scholar
• GründerGKungelMEbrechtMGöröcsTModellSAripiprazole: pharmacodynamics of a dopamine partial agonist for the treatment of schizophreniaPharmacopsychiatry200639Suppl 1S21S2516508892
   PubMed Web of Science ®Google Scholar
• ItoHTakanoHArakawaREffects of dopamine D2 receptor partial agonist antipsychotic aripiprazole on dopamine synthesis in human brain measured by PET with L-[β-11C]DOPAPLoS One201279e4648823029533
   PubMed Web of Science ®Google Scholar
• TadoriYForbesRAMcQuadeRDKikuchiTIn vitro pharmacology of aripiprazole, its metabolite and experimental dopamine partial agonists at human dopamine D2 and D3 receptorsEur J Pharmacol2011668335536521816144
   PubMed Web of Science ®Google Scholar
• TakahataKItoHTakanoHStriatal and extrastriatal dopamine D2 receptor occupancy by the partial agonist antipsychotic drug aripiprazole in the human brain: a positron emission tomography study with [¹¹C]raclopride and [¹¹C]FLB457Psychopharmacology (Berl)2012222116517222237854
   PubMed Web of Science ®Google Scholar
• MillerDAtypical antipsychotics: sleep, sedation, and efficacyPrim Care Companion J Clin Psychiatry20046Suppl 23716001094
   PubMedGoogle Scholar
• Abilify® (aripiprazole): summary of product characteristics (online)LondonEuropean Medicines Agency Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000471/WC500020170.pdfAccessed September 27, 2013
   Google Scholar
• MallikaarjunSSalazarDEBramerSLPharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteersJ Clin Pharmacol200444217918714747427
   PubMed Web of Science ®Google Scholar
• BoultonDWKolliaGDMallikaarjunSKornhauserDMLack of a pharmacokinetic drug-drug interaction between lithium and valproate when co-administered with aripiprazoleJ Clin Pharm Ther20123756557022943745
   PubMed Web of Science ®Google Scholar
• McIntyreRSSoczynskaJKWoldeyohannesHOMirandaAKonarskiJZAripiprazole: pharmacology and evidence in bipolar disorderExpert Opin Pharmacother2007871001100917472545
   PubMed Web of Science ®Google Scholar
• ShastryCSShafeequeAAAshwathnarayanaBJEffect of combination of aripiprazole with carbamazepine and fluvoxamine on liver functions in experimental animalsIndian J Pharmacol20134512112523716885
   PubMed Web of Science ®Google Scholar
• HendsetMMoldenEEnoksenTBRefsumHHermannMThe effect of coadministration of duloxetine on steady-state serum concentration of risperidone and aripiprazole: a study based on therapeutic drug monitoring dataTher Drug Monit20103278779021068650
   PubMed Web of Science ®Google Scholar
• ZhuHJAppelDIPetersonYKWangZMarkowitzJSIdentification of selected therapeutic agents as inhibitors of carboxylesterase 1: potential sources of metabolic drug interactionsToxicology2010270596520097249
   PubMed Web of Science ®Google Scholar
• KanbaSKawasakiHIshigookaJSakamotoKKinoshitaTKurokiTA placebo-controlled, double-blind study of the efficacy and safety of aripiprazole for the treatment of acute manic or mixed episodes in Asian patients with bipolar I disorder (the AMAZE study)World J Biol Psychiatry Epub4302012
   Web of Science ®Google Scholar
• SachsGSanchezRMarcusRAripiprazole Study GroupAripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled studyJ Psychopharmacol200620453654616401666
   PubMed Web of Science ®Google Scholar
• KeckPEJrMarcusRTourkodimitrisSAripiprazole Study GroupA placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar maniaAm J Psychiatry200316091651165812944341
   PubMed Web of Science ®Google Scholar
• El-MallakhRSVietaERollinLMarcusRCarsonWHMcQuadeRA comparison of two fixed doses of aripiprazole with placebo in acutely relapsed, hospitalized patients with bipolar disorder I (manic or mixed) in subpopulations (CN138-007)Eur Neuropsychopharmacol20102077678320728318
   PubMed Web of Science ®Google Scholar
• FindlingRLNyilasMForbesRAAcute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: a randomized, double-blind, placebo-controlled studyJ Clin Psychiatry200970101441145119906348
   PubMed Web of Science ®Google Scholar
• FindlingRLCorrellCUNyilasMAripiprazole for the treatment of pediatric bipolar I disorder: a 30-week, randomized, placebo-controlled studyBipolar Disord201315213814923437959
   PubMed Web of Science ®Google Scholar
• YoungAHOrenDALowyAAripiprazole monotherapy in acute mania: 12-week randomised placebo- and haloperidol-controlled studyBr J Psychiatry20091941404819118324
   PubMed Web of Science ®Google Scholar
• KeckPEOrsulakPJCutlerAJCN138-135 Study GroupAripiprazole monotherapy in the treatment of acute bipolar I mania: a randomized, double-blind, placebo- and lithium-controlled studyJ Affect Disord20091121–3364918835043
   PubMed Web of Science ®Google Scholar
• VietaEBourinMSanchezRAripiprazole Study GroupEffectiveness of aripiprazole v. haloperidol in acute bipolar mania: double-blind, randomised, comparative 12-week trialBr J Psychiatry200518723524216135860
   PubMed Web of Science ®Google Scholar
• SinghMTreatment efficacy and concomitant benzodiazepine use with aripiprazole versus olanzapine in acute bipolar maniaEur Neuropsychopharmacol2009193S536
   Web of Science ®Google Scholar
• ZimbroffDLMarcusRNManosGManagement of acute agitation in patients with bipolar disorder: efficacy and safety of intramuscular aripiprazoleJ Clin Psychopharmacol200727217117617414241
   PubMed Web of Science ®Google Scholar
• VietaET’joenCMcQuadeRDEfficacy of adjunctive aripiprazole to either valproate or lithium in bipolar mania patients partially nonresponsive to valproate/lithium monotherapy: a placebo-controlled studyAm J Psychiatry20081651316132518381903
   PubMed Web of Science ®Google Scholar
• El-MallakhRSMarcusRBaudeletCMcQuadeRCarsonWHOwenRA 40-week double-blind aripiprazole versus lithium follow-up of a 12-week acute phase study (total 52 weeks) in bipolar I disorderJ Affect Disord2012136325826622209190
   PubMed Web of Science ®Google Scholar
• MarcusRKhanARollinLEfficacy of aripiprazole adjunctive to lithium or valproate in the long-term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: a multicenter, double-blind, randomized studyBipolar Disord201113213314421443567
   PubMed Web of Science ®Google Scholar
• VietaEOwenRBaudeletCMcQuadeRDSanchezRMarcusRNAssessment of safety, tolerability and effectiveness of adjunctive aripiprazole to lithium/valproate in bipolar mania: a 46-week, open-label extension following a 6-week double-blind studyCurr Med Res Opin20102661485149620429835
   PubMed Web of Science ®Google Scholar
• CarlsonBXKetterTASunWAripiprazole in combination with lamotrigine for the long-term treatment of patients with bipolar I disorder (manic or mixed): a randomized, multicenter, double-blind study (CN138-392)Bipolar Disord2012141415322329471
   PubMed Web of Science ®Google Scholar
• KeckPEJrCalabreseJRMcQuadeRDAripiprazole Study GroupA randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorderJ Clin Psychiatry200667462663716669728
   PubMed Web of Science ®Google Scholar
• KeckPEJrCalabreseJRMcIntyreRSAripiprazole Study GroupAripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placeboJ Clin Psychiatry200768101480149117960961
   PubMed Web of Science ®Google Scholar
• FountoulakisKNVietaESchmidtFAripiprazole monotherapy in the treatment of bipolar disorder: a meta-analysisJ Affect Disord2011133336137021040979
   PubMed Web of Science ®Google Scholar
• FountoulakisKNGondaXVietaESchmidtFTreatment of psychotic symptoms in bipolar disorder with aripiprazole monotherapy: a meta-analysisAnn Gen Psychiatry200982720043829
   PubMedGoogle Scholar
• CiprianiARendellJMGeddesJRHaloperidol alone or in combination for acute maniaCochrane Database Syst Rev20063CD00436216856043
   PubMedGoogle Scholar
• PerlisRHWelgeJAVornikLAHirschfeldRMKeckPEJrAtypical antipsychotics in the treatment of mania: a meta-analysis of randomized, placebo-controlled trialsJ Clin Psychiatry20066750951616669715
   PubMed Web of Science ®Google Scholar
• ScherkHPajonkFGLeuchtSSecond-generation antipsychotic agents in the treatment of acute mania: a systematic review and meta-analysis of randomized controlled trialsArch Gen Psychiatry20076444245517404121
   PubMed Web of Science ®Google Scholar
• SmithLACorneliusVWarnockATacchiMJTaylorDPharmacological interventions for acute bipolar mania: a systematic review of randomized placebo-controlled trialsBipolar Disord2007955156017845269
   PubMed Web of Science ®Google Scholar
• SachsGSGaulinBDGutierrez-EsteinouRAntimanic response to aripiprazole in bipolar I disorder patients is independent of the agitation level at baselineJ Clin Psychiatry2007681377138317915976
   PubMed Web of Science ®Google Scholar
• YildizAVietaELeuchtSBaldessariniRJEfficacy of antimanic treatments: meta-analysis of randomized, controlled trialsNeuropsychopharmacology201136237538920980991
   PubMed Web of Science ®Google Scholar
• MuralidharanKAliMSilveiraLEEfficacy of second generation antipsychotics in treating acute mixed episodes in bipolar disorder: a meta-analysis of placebo-controlled trialsJ Affect Disord2013150240841423735211
   PubMed Web of Science ®Google Scholar
• TohenMVietaEAntipsychotic agents in the treatment of bipolar maniaBipolar Disord200911Suppl 2455419538685
   PubMed Web of Science ®Google Scholar
• KaneJMSanchezRPerryPPAripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled studyJ Clin Psychiatry201273561762422697189
   PubMed Web of Science ®Google Scholar
• DratcuLBobmanuelSDaviesWA UK panel consensus on the initiation of aripiprazole for the treatment of bipolar maniaInt J Psychiatry Clin Pract201216424425822809129
   PubMed Web of Science ®Google Scholar
• YathamLNKennedySHParikhSVCanadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013Bipolar Disord201315114423237061
   PubMed Web of Science ®Google Scholar
• GoodwinGMConsensus Group of the British Association for PsychopharmacologyEvidence-based guidelines for treating bipolar disorder: revised second edition – recommendations from the British Association for PsychopharmacologyJ Psychopharmacol200923434638819329543
   PubMed Web of Science ®Google Scholar
• De FazioPGirardiPMainaGAripiprazole in acute mania and long-term treatment of bipolar disorder: a critical review by an Italian working groupClin Drug Investig20103012827841
   PubMed Web of Science ®Google Scholar
• Bristol-Myers-SquibbOPEN. Abilify (aripiprazole) Summary of Product Characteristics92011
   Google Scholar
• KaneJMBarnesTRCorrellCUEvaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder: a post hoc analysis of pooled data from short- and long-term aripiprazole trialsJ Psychopharmacol20102471019102920008446
   PubMed Web of Science ®Google Scholar
• DhillonSAripiprazole: a review of its use in the management of mania in adults with bipolar I disorderDrugs201272113316222191800
   PubMed Web of Science ®Google Scholar
• CorrellCUManuPOlshanskiyVNapolitanoBKaneJMMalhotraAKCardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescentsJAMA2009302161765177319861668
   PubMed Web of Science ®Google Scholar
• FagioliniAFrankEScottJATurkinSKupferDJMetabolic syndrome in bipolar disorder: findings from the Bipolar Disorder Center for PennsylvaniansBipolar Disord20057542443016176435
   PubMed Web of Science ®Google Scholar
• American Diabetes AssociationAmerican Psychiatric AssociationAmerican Association of Clinical EndocrinologistsNorth American Association for the Study of ObesityConsensus development conference on antipsychotic drugs and obesity and diabetesDiabetes Care200427259660114747245
   PubMed Web of Science ®Google Scholar
• KempDECalabreseJRTranQVPikalovAEudiconeJMBakerRAMetabolic syndrome in patients enrolled in a clinical trial of aripiprazole in the maintenance treatment of bipolar I disorder: a post hoc analysis of a randomized, double-blind, placebo-controlled trialJ Clin Psychiatry20107191138114420492838
   PubMed Web of Science ®Google Scholar
• YoungAHGrunzeHPhysical health of patients with bipolar disorderActa Psychiatr Scand Suppl201344231023581787
   PubMedGoogle Scholar
• VietaEMurruAPueyoMJGuidelines on the management of bipolar disorder in CatalunyaBarcelonaDepartment of Health Available from: http://www.gencat.cat/salut/depsan/units/aatrm/pdf/guia_trastorn_bipolar_aiaqs_2010ca.pdfAccessed January 17, 2014 Catalan
   Google Scholar
• ColomFVietaEDabanCPacchiarottiISanchez-MorenoJClinical and therapeutic implications of predominant polarity in bipolar disorderJ Affect Disord200693131716650901
   PubMed Web of Science ®Google Scholar